Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

Fadi Fakhouri, MD, PhD,1 Maryvonne Hourmant, MD, PhD,1 Josep M. Campistol, MD,2 Spero R. Cataland, MD,2 Mario Espinosa, MD,4 A. Osama Gaber, MD,5 Jan Menne, MD,6 Enrico E. Minetti, MD,7 François Provot, MD,8 Eric Rondeau, MD, PhD,9 Piero Ruggenenti, MD,10 Laurent E. Weekers, MD,11 Masayo Ogawa, MD,12 Camille L. Bedrosian, MD,12 and Christophe M. Legendre, MD13

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end-organ damage. Eculizumab, a terminal complement inhibitor approved for aHUS treatment, was reported to improve hematologic and renal parameters in 2 prior prospective phase 2 studies. This is the largest prospective study of eculizumab in aHUS to date, conducted in an adult population.

Study Design: Open-label single-arm phase 2 trial.

Setting & Participants: Patients 18 years or older with aHUS (platelet count < 150 x 10^3/μL, hemoglobin ≤ lower limit of normal, lactate dehydrogenase ≥ 1.5 x upper limit of normal [ULN], and serum creatinine ≥ ULN) were included in this multicenter multinational study.

Intervention: Intravenous eculizumab (900 mg/wk for 4 weeks, 1,200 mg at week 5 and then every 2 weeks) for 26 weeks.

Outcomes & Measurements: Primary end point was complete TMA response within 26 weeks, defined as hematologic normalization (platelet count ≥ 150 x 10^3/μL, LDH ≤ ULN), and preservation of kidney function (< 25% serum creatinine increase from baseline), confirmed by 2 or more consecutive measurements obtained 4 or more weeks apart.

Results: 41 patients were treated; 38 (93%) completed 26 weeks of treatment. 30 (73%) were included during their first TMA manifestation. 30 (73%) had complete TMA response. Platelet counts and estimated glomerular filtration rates increased from baseline ($P < 0.001). All 35 patients on baseline plasma exchange/plasma infusion discontinued by week 26. Of 24 patients requiring baseline dialysis, 5 recovered kidney function before eculizumab initiation and 15 of the remaining 19 (79%) discontinued dialysis during eculizumab treatment. No patients lost existing transplants. Quality-of-life measures were significantly improved. Two patients developed meningococcal infections; both recovered, and 1 remained on eculizumab treatment.

Limitations: Single-arm open-label design.

Conclusions: Results highlight the benefits of eculizumab in adult patients with aHUS: improvement in hematologic, renal, and quality-of-life parameters; dialysis discontinuation; and transplant protection.

Am J Kidney Dis. 68(1):84-93. © 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INDEX WORDS: Eculizumab; Soliris; terminal complement inhibitor; atypical hemolytic uremic syndrome (aHUS); thrombotic microangiopathy (TMA); kidney disease; platelet count; hemoglobin; lactate dehydrogenase (LDH); renal function; hematologic normalization; TMA response; adults; clinical trial.

From the 1Department of Nephrology and Immunology, UMR 643, CHU de Nantes, Nantes, France; 2Nephrology and Urology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain; 3Division of Hematology, The Ohio State University Medical Center, Columbus, OH; 4Nefrología, Hospital Universitario Reina Sofia, Córdoba, Spain; 5Houston Methodist Research Institute, Houston, TX; 6Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; 7Division of Nephrology, Careggi University Hospital, Florence, Italy; 8Department of Nephrology, CHU Liège, Liège; 9Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon and Université Paris VI, Paris, France; 10IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Bergamo, Italy; 11Service of Nephrology, Diábiosis and Transplantation, Centre Hospitalier Universitaire, Liège, Belgium; 12Alexion Pharmaceuticals, Inc, Cheshire, CT; and 13Adult Kidney Transplant Unit, Université Paris Descartes and Hôpital Necker, Paris, France.

Received July 14, 2015. Accepted in revised form December 28, 2015. Originally published online March 21, 2016.

Trial Registration: www.ClinicalTrials.gov; study number: NCT01194973.

Address correspondence to Fadi Fakhouri, MD, PhD, Department of Nephrology and Immunology, UMR 643, CHU de Nantes, 27 Rue la Pérouse, 44000 Nantes Cedex 1, France. E-mail: fadi.fakhouri@univ-nantes.fr

© 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 0272-6386.

http://dx.doi.org/10.1053/j.ajkd.2015.12.034
A typical hemolytic uremic syndrome (aHUS) is a rare, often progressive, and life-threatening cause of systemic thrombotic microangiopathy (TMA) resulting from long-term uncontrolled alternative complement activation.\(^1\) Complement gene mutations or factor H autoantibodies have been identified in up to 70% of patients with aHUS,\(^4\) but are not required for diagnosis. Although frequently diagnosed during childhood, the majority (58%) of aHUS cases occur in patients older than 18 years.\(^5\)

The underlying pathophysiology associated with aHUS involves endothelial cell activation, platelet activation and aggregation, leukocyte recruitment, and a systemic procoagulant state, leading to TMA.\(^3\) Decreased kidney function and end-stage renal disease (ESRD) are recognized as severe complications of aHUS. Forty-six percent of patients have already reached ESRD by the time aHUS is diagnosed,\(^5\) and the risk for kidney failure and death increases with disease duration.\(^4\) More rarely, TMA in aHUS also leads to significant morbidity in other vital organ systems, including neurologic, cardiovascular, pulmonary, and gastrointestinal.\(^1\)历史性地，aHUS已将包括血浆交换/血浆输注（PE/PI）在内的治疗手段应用于成人患者。成人aHUS患者的治疗结果较差，以65%的进展至ESRD或在1年内的死亡率。\(^5\) The long-term outlook is equally dire because up to 79% of patients have permanently decreased kidney function or ESRD or die within 3 years.\(^7\) Kidney transplantation in patients with aHUS historically also has been unsuccessful because approximately 50% to 71% of patients with aHUS have transplant failure within 1 year as a result of a subsequent TMA manifestation.\(^5\,10\)

Eculizumab (Soliris; Alexion Pharmaceuticals, Inc) is a humanized monoclonal antibody that blocks cleavage of the terminal complement protein C5 into the proinflammatory C5a and lytic C5b-9.\(^6\) In 2011, eculizumab became the first and only approved treatment for aHUS.\(^12,13\) The efficacy and safety of eculizumab in aHUS were first demonstrated in 2 prospective clinical trials of primarily adult patients, either with evidence of progressing TMA or with long disease duration and chronic kidney disease (CKD).\(^14,15\) Both pivotal trials included patients with native kidneys and kidney transplants.\(^14,15\) The current study is the first and largest study of eculizumab in an exclusively adult population with severe aHUS and was conducted to satisfy requirements for full approval in the United States. This report presents results of the primary analysis based on a 26-week eculizumab treatment period.

**METHODS**

**Study Design and Approval**

This was an open-label, single-arm, multicenter, phase 2 trial in adult patients with aHUS to assess the efficacy of eculizumab in inhibiting complement-mediated TMA. The study consisted of a 7-day screening period, 26-week treatment period, and an extension period in which patients could receive eculizumab for up to 2 years. Patients 18 years or older with aHUS, platelet counts <150 × 10^9/L, hemoglobin levels at or less than the lower limit of normal range, lactate dehydrogenase (LDH) levels ≥ 1.5 times the upper limit of normal range, and serum creatinine levels at or greater than the upper limit of normal range at screening were enrolled at 23 centers in North America and Europe from August 2010 through September 2011. An identified complement abnormality was not required for enrollment, although complement mutation analysis was performed in all patients upon study entry. Use of PE/PI was not a prerequisite for inclusion. Patients must have been vaccinated against *Neisseria meningitidis*; if vaccination occurred fewer than 14 days prior to receiving the first eculizumab dose, patients received prophylactic antibiotics until at least 14 days after vaccination. Key exclusion criteria were described previously.\(^14\)

The protocol was approved by the institutional review board at each participating center or by an independent ethics committee (Table S1, available as online supplementary material) and was conducted in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines and the Declaration of Helsinki. All patients provided written informed consent before entry into the study.

**Dosages**

Eculizumab dosages were based on previous clinical studies and were administered intravenously at 900 mg once a week for 4 weeks, 1,200 mg at week 5, and then 1,200 mg every 2 weeks. Patients who discontinued eculizumab therapy were followed up for 8 weeks to assess safety parameters and for 1 year to assess aHUS disease status and outcomes.

**End Points**

Efficacy end points were within 26 weeks of the treatment (primary analysis) and were defined elsewhere unless specified here. The primary end point was proportion of patients who achieved complete TMA response, defined as hemato logic normalization (platelet count ≥ 150 × 10^9/L and LDH ≤ upper limit of normal range) and preservation of kidney function (< 25% increase in serum creatinine from baseline), confirmed by 2 or more consecutive measurements obtained 4 or more weeks apart. Secondary end points included modified complete TMA response, defined as hematologic normalization (platelets and LDH) and improvement in kidney function (ie, ≥ 25% decrease in serum creatinine level from baseline), TMA event-free status (absence of platelet count decrease ≥ 25% from baseline, PE/PI, and new dialysis for ≥ 12 weeks), TMA intervention rate (number of PE/PI and/or new dialysis events per patient-days), hematologic normalization, and improvements in hematologic parameters (platelet count, LDH, and hemoglobin levels) and kidney function measures (estimated glomerular filtration rate [eGFR]) and CKD improvement by ≥ 1 stage. Categorical end points were required to be sustained for 2 or more consecutive measurements obtained 4 or more weeks apart. All enrolled patients were included in analyses of response variable end points (eg, complete TMA response, modified complete TMA response, TMA event-free status, platelet count normalization, LDH normalization, hematologic normalization, improvement in hemoglobin level by ≥ 2 g/dL, eGFR improvement by ≥ 15 mL/min/1.73 m^2, and CKD improvement by ≥ 1 stage). If a patient did not have sufficient data to meet the achievement criteria for a response variable end point and sustain achievement for 28 days, the patient could not achieve the end point. Data may be missing if patients did not attend the week 26 visit or no measurement was recorded for the following continuous variables: mean change from baseline in platelet count and eGFR, mean eGFR and serum creatinine level, and CKD stage. Health-related quality of life was assessed by the
EQ-5D (EuroQol Group) US time trade-off\textsuperscript{17} as described previously,\textsuperscript{14} the Functional Assessment of Chronic Illness Therapy–Fatigue (FACT-F),\textsuperscript{18} and the 36-Item Short Form Health Survey (SF-36)\textsuperscript{19} questionnaires. The safety and tolerability of eculizumab was assessed by reported adverse events (AEs), reviewed by an independent data monitoring committee. The presence of neutralizing human anti-human antibodies was assessed at study days 0 and 28 and at the end of study with an electrochemiluminescence bridging assay, which conjugated eculizumab to biotin and to SulfoTag (Meso Scale Diagnostics, LLC).

**Statistical Analyses**

All analyses were performed for the intention-to-treat population, defined as all patients who received 1 or more dose of eculizumab, using the SAS System (version 9.2; SAS Institute Inc). Statistical tests were assessed at the 2-sided \( \alpha = 5\% \) level without adjustment for multiplicity. Complete TMA response, modified complete TMA response, and proportion of patients with a \( \geq 15 \text{mL/min/1.73 m}^2 \) change in eGFR were assessed using the Clopper-Pearson method for responder rate at the 1-sided \( \alpha = 5\% \) level. For all composite end points, patients were censored at the last follow-up day if baseline or postbaseline values were missing for any component; patients unable to be assessed for all components were considered treatment failures. Effect size for the EQ-5D was calculated as Cohen d standardized mean change from baseline. Baseline demographic and clinical characteristics and efficacy outcomes of subgroups of patients who did and did not require dialysis at study baseline were analyzed post hoc.

**RESULTS**

**Patients**

Forty-four adult patients were enrolled, 41 were treated, and 38 (93\%) completed the 26-week study period (Fig 1). Patient demographics, disease characteristics, and baseline laboratory values in the intention-to-treat population and for patients who did (\( n = 24 \)) and did not (\( n = 17 \)) require dialysis use at baseline are summarized in Table 1. The study population was mainly white (93\%) and female (68\%), with a mean age of 40 years. Twenty-one (51\%) patients had 1 or more identified complement genetic mutation, autoantibody, or deletion. Thirty (73\%) patients had aHUS newly diagnosed and were enrolled in the study during their first clinical TMA manifestation. Thirty-five (85\%) patients received eculizumab after undergoing PE/PI during the current manifestation; 6 (15\%) received first-line eculizumab without prior PE/PI. Twenty-four (59\%) patients were on dialysis at baseline for a median pretreatment duration of 13 (range, 2-2,376) days (measured in 20 patients; the other 4 initiated dialysis between days 0 and 14), including 13 (range, 2-26) days during the current manifestation (\( n = 18 \)). Nine (22\%) patients had a history of prior kidney transplantation.

**Efficacy**

**Primary End Point**

There was complete TMA response in 30 patients (73\%; 95\% confidence interval [CI], 57\%-86\%; \( N = 41 \)) by 26 weeks (Table 2). Criteria for the primary end point were met by 17 of 24 (71\%) patients requiring dialysis and 13 of 17 (77\%) who did not require dialysis at baseline. Overall, median time to complete TMA response was 56 (range, 2-147) days.

**Other TMA Outcomes**

By 26 weeks, modified complete TMA response was achieved by 23 patients (56\%; 95\% CI, 40\%-72\%; \( N = 41 \)) at a median of 57 (range, 2-147) days. TMA event-free status was reached by 37 patients (90\%; 95\% CI, 77\%-97\%; \( N = 41 \); Table 2) after a mean of 6.1 ± 14.3 (standard deviation) days. The median TMA intervention rate significantly decreased from 0.6 (range, 0-1.4) per patient before treatment to 0 (range, 0-0.6) per patient while on eculizumab therapy (\( P < 0.001 \)). Of 35 patients on PE/PI at baseline, all (100\%) discontinued PE/PI during the study period (range, day 0-163). Four of the 6 patients not receiving PE/PI at baseline initiated PE/PI during the study period. However, no patients who remained on eculizumab treatment at week 26 were receiving PE/PI.

**Hematologic Outcomes**

Forty patients (98\%; 95\% CI, 87\%-100\%; \( N = 41 \)) had platelet count normalization (Table 2) at a median...
of 8 (range, 0-84) days. Improvement in platelet counts from baseline was significant at 1 week (mean change, 104 ± 115 × 10^3/μL) and was maintained to 26 weeks (mean change from baseline, 135 ± 114 × 10^3/μL; n = 27; P ≤ 0.001 at all time points; Fig 2). There was LDH level normalization in 37 patients (90%; 95% CI, 77%-97%; N = 41) at a median of 54 (range, 2-146) days. At 26 weeks, mean change from baseline in LDH levels was −323 ± 590 U/L (P = 0.008; n = 28). There was hematologic normalization in 36 patients (88%; 95% CI, 74%-96%; N = 41) by 26 weeks, at a median of 55 (range, 2-146) days. A total of 25 patients (61%; 95% CI, 45%-76%; N = 41) had an improvement in hemoglobin level of at least 2 g/dL by week 26, at a median of 25 (range, 7-113) days. Mean change from baseline in hemoglobin level after 26 weeks was 3.3 ± 3.2 g/dL (P < 0.001; n = 25).
Table 2. TMA, Hematologic, and Kidney Disease Outcomes for Eculizumab in Adult Patients With aHUS, by 26 Weeks of Treatment

<table>
<thead>
<tr>
<th>Primary and Secondary End Points</th>
<th>ITT Population (N = 41)</th>
<th>Dialysisa (n = 24)</th>
<th>No Dialysisa (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary end point</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete TMA responseb</td>
<td>30 (73%)</td>
<td>17 (71%)</td>
<td>13 (77%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>57%-86%</td>
<td>49%-87%</td>
<td>50%-93%</td>
</tr>
<tr>
<td><strong>TMA outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified complete TMA responseb</td>
<td>23 (56%)</td>
<td>15 (63%)</td>
<td>8 (47%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>40%-72%</td>
<td>41%-81%</td>
<td>23%-72%</td>
</tr>
<tr>
<td>TMA event-free statusb</td>
<td>37 (90%)</td>
<td>22 (92%)</td>
<td>15 (88%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>77%-97%</td>
<td>73%-99%</td>
<td>64%-99%</td>
</tr>
<tr>
<td><strong>Hematologic outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet count normalizationb</td>
<td>40 (98%)</td>
<td>23 (96%)</td>
<td>17 (100%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>87%-100%</td>
<td>79%-100%</td>
<td>81%-100%</td>
</tr>
<tr>
<td>Change from baseline in platelet count, (\times 10^3) /mL (n = 27)c</td>
<td>135 ± 114</td>
<td>163 ± 120</td>
<td>87 ± 88</td>
</tr>
<tr>
<td>LDH normalizationb</td>
<td>37 (90%)</td>
<td>23 (96%)</td>
<td>14 (82%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>77%-97%</td>
<td>79%-100%</td>
<td>57%-96%</td>
</tr>
<tr>
<td>Hematologic normalizationb</td>
<td>36 (88%)</td>
<td>22 (92%)</td>
<td>14 (82%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>74%-96%</td>
<td>73%-99%</td>
<td>57%-96%</td>
</tr>
<tr>
<td>Improvement in hemoglobin by (\geq 2) g/dLb</td>
<td>25 (61%)</td>
<td>16 (67%)</td>
<td>9 (53%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>45%-76%</td>
<td>45%-84%</td>
<td>28%-77%</td>
</tr>
<tr>
<td><strong>Kidney disease outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eGFR improvement by (\geq 15) mL/min/1.73 m²b</td>
<td>22 (54%)</td>
<td>15 (63%)</td>
<td>7 (41%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>37%-69%</td>
<td>41%-81%</td>
<td>18%-67%</td>
</tr>
<tr>
<td>Change from baseline in eGFR, mL/min/1.73 m² (n = 29)d</td>
<td>29 ± 24</td>
<td>35 ± 22</td>
<td>20 ± 24</td>
</tr>
<tr>
<td>95% CI</td>
<td>39%-64%</td>
<td>42%-83%</td>
<td>16%-63%</td>
</tr>
<tr>
<td>eGFR, mL/min/1.73 m² (n = 29)d</td>
<td>47 ± 24</td>
<td>46 ± 23</td>
<td>51 ± 28</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL (n = 29)d</td>
<td>1.7 ± 0.8</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Patients on dialysis at baseline who discontinued it</td>
<td>20/24 (83%)</td>
<td>20/24 (83%)</td>
<td>—</td>
</tr>
<tr>
<td>Discontinued before the initial eculizumab dose, but within the baseline period</td>
<td>5/24 (21%)</td>
<td>5/24 (21%)</td>
<td>—</td>
</tr>
<tr>
<td>Discontinued during the study period</td>
<td>15/19 (79%)</td>
<td>15/19 (79%)</td>
<td>—</td>
</tr>
<tr>
<td>Patients not on dialysis at baseline who initiated in study period</td>
<td>4/17 (24%)</td>
<td>—</td>
<td>4/17 (24%)</td>
</tr>
<tr>
<td>CKD stagea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2 (5%)</td>
<td>0 (0%)</td>
<td>2 (12%)</td>
</tr>
<tr>
<td>2</td>
<td>6 (15%)</td>
<td>5 (21%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>3a</td>
<td>8 (20%)</td>
<td>6 (25%)</td>
<td>2 (12%)</td>
</tr>
<tr>
<td>3b</td>
<td>6 (15%)</td>
<td>2 (8%)</td>
<td>4 (24%)</td>
</tr>
<tr>
<td>4</td>
<td>2 (5%)</td>
<td>1 (4%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>5</td>
<td>5 (12%)</td>
<td>4 (17%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>12 (29%)</td>
<td>6 (25%)</td>
<td>6 (35%)</td>
</tr>
</tbody>
</table>

Note: Unless otherwise indicated, values for categorical variables are given as number (percentage) or n/N (percentage); values for continuous variables are given as mean ± standard deviation. Complete TMA response was defined as platelet count \(\geq 150 \times 10^3\) /mL, LDH at ULN or less, and <25% increase in serum creatinine from baseline (ie, preservation of kidney function) and was confirmed by 2 or more consecutive measurements obtained 4 or more weeks apart. Modified complete TMA response was defined as platelet count \(\geq 150 \times 10^3\) /mL, LDH at ULN or less, and \(\geq 25\) % improvement in serum creatinine level from baseline (ie, improvement in kidney function). TMA event-free status was defined as the absence of the following for 12 or more weeks: \(>25\) % decrease from baseline in platelet count, PE/PI while receiving eculizumab, and new dialysis. Categorical end points were required to be sustained for 2 or more consecutive measurements obtained 4 or more weeks apart. Conversion factors for hemoglobin in g/dL to g/L; for serum creatinine in mg/dL to \(\mu\)mol/L, \(\times 88.4\).

Abbreviations: aHUS, atypical hemolytic uremic syndrome; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ITT, intention-to-treat; LDH, lactate dehydrogenase; NA, not available; PE/PI, plasma exchange/plasma infusion; TMA, thrombotic microangiopathy; ULN, upper limit of normal range.

a Patients were grouped by dialysis use at study baseline. Baseline dialysis was defined as any occurring within 7 days prior to and up to 14 days after the first eculizumab dose.

b N = 41. All enrolled patients were included in the analysis. If a patient did not have sufficient data to meet the achievement criteria for a response variable end point and sustain achievement for 28 days, the patient could not achieve the end point.

c Data for 14 of 41 (34%) patients were not available at week 26. Data were missing if the patient did not attend the week 26 visit or no measurement was recorded.

d Data for 12 of 41 (29%) patients were not available at week 26. Data were missing if the patient did not attend the week 26 visit or no measurement was recorded.
Kidney Disease Outcomes

Twenty-two patients (54%; 95% CI, 37%-69%; N = 41) had eGFR improvement of \( \geq 15 \text{ mL/min/1.73 m}^2 \) by week 26 (Table 2). Significant improvements in eGFRs from baseline were achieved by week 1 (\( P < 0.05 \)) and were maintained over 26 weeks of treatment (Fig 3). Mean change from baseline in eGFRs at 26 weeks was 29 ± 24 mL/min/1.73 m\(^2\) (\( P < 0.001; \ n = 29 \)). Improvements in eGFRs were greater for patients on dialysis at baseline compared with those who did not.

Figure 2. Improvement in platelet count over 26 weeks of eculizumab treatment. Bars represent standard error. \*P ≤ 0.001. Only \( n > 5 \) are shown.

Figure 3. Improvement in estimated glomerular filtration rate (eGFR) over 26 weeks of eculizumab treatment. Bars represent standard error. \*P ≤ 0.05; \ †P ≤ 0.01. Only \( n > 5 \) are shown.
not require baseline dialysis (Table 2). At week 26, mean serum creatinine level was 1.7 ± 0.8 mg/dL (n = 29). During the 26-week study period, 26 patients (63%; N = 41) improved by 1 or more stage of CKD. Of the 24 patients on dialysis at baseline, 20 (83%) discontinued dialysis. Of these, 5 discontinued dialysis before receiving the initial dose of eculizumab. Of the other 19 patients, 15 (79%) discontinued before week 26, after a posttreatment median of 29 (range, 1-180) days. Four of the 19 patients continued dialysis at week 26 (Fig 4). No patient who discontinued dialysis needed to resume dialysis during the 26-week study period. Of the 17 patients not on dialysis at baseline, 4 (24%) initiated new dialysis during the study (on days 36, 62, 120, and 160), including 2 who discontinued prior to and 2 who remained on dialysis at week 26. Thus, at week 26, a total of 6 patients (15%) were receiving dialysis, compared with 19 (46%) at the start of eculizumab therapy.

Health-Related Quality of Life

Patient health-related quality of life was also improved after 26 weeks of eculizumab therapy (Fig 5). Thirteen of 23 (57%) evaluable patients met criteria for clinically important improvements (≥0.06) on the US time trade-off index in the EQ-5D questionnaire by 26 weeks, and mean change from baseline was significant (P < 0.001). FACIT-F and SF-36 score changes from baseline after 26 weeks are presented in Item S1.

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic and pharmacodynamic data are presented in Item S2.

Safety

All patients in the study reported at least 1 treatment-emergent AE (Table S2). Serious treatment-emergent AEs were reported by 18 patients (44%; Table S3), 1 of which (meningococcal meningitis; serogroup unknown) led to a permanent eculizumab therapy discontinuation at day 98. A serious treatment-emergent AE of meningococcal sepsis (serogroup B) was reported in 1 patient, who was hospitalized and recovered without sequelae; eculizumab treatment was not interrupted. In both cases of meningococcal infection, the patients had been immunized against serogroups A, C, W, and Y, but had not received long-term antibiotic prophylaxis (see additional details in Table S4). No deaths or unexpected safety concerns occurred during the study.

Prior to receiving the first dose of eculizumab, elevated alanine transaminase and aspartate aminotransferase levels were noted in 14 (34%) and 19 (46%) of 41 patients, respectively. In addition, transient liver enzyme level elevations were observed during the study. Most patients had normalization of enzyme levels during eculizumab treatment; at week 26, 3 of 38 (8%) patients had elevated alanine transaminase levels and 1 of 38 (3%) had elevated aspartate aminotransferase levels.

DISCUSSION

This study, which to our knowledge is the largest prospective trial of eculizumab in aHUS to date, demonstrates the efficacy of eculizumab in an exclusively adult population with severe aHUS and predominantly native kidneys, including patients who

---

**Figure 4.** Dialysis use at baseline and during the study.
had not received PE/PI prior to enrollment. The primary end point of complete TMA response was reached by the majority of patients (73%) after 26 weeks, and high proportions of patients saw improvements in key hematologic and kidney disease outcomes. These benefits were observed in patients who did and did not require dialysis at study baseline. Importantly, 79% of patients requiring dialysis at baseline discontinued dialysis after the initiation of eculizumab therapy.

In addition, improvements in other outcomes related to the overall well-being of patients with aHUS, including discontinuation of PE/PI, contribute to the important clinical benefits of eculizumab. It should be noted that 4 patients with no history of PE/PI at baseline initiated new PE/PI during the study and received it concomitantly with eculizumab therapy for a median duration of 28 (range, 6-81) days. No patients were on PE/PI at week 26. Due to the single-arm open-label study design, it was not possible to evaluate the effects of supportive care in these particular patients.

The recovery of kidney function and other clinical benefits shown in the current trial stand in sharp contrast to the natural history of aHUS. In a large case series of patients with aHUS before the availability of eculizumab, 81% of adult patients required dialysis at onset and 56% could be expected to progress to ESRD or die in the first year after diagnosis despite the use of PE/PI in a large proportion of these patients. In the current study, platelet count normalization occurred more rapidly than improvements in hemoglobin levels or kidney function (ie, serum creatinine level in modified complete TMA response), although significant improvements in eGFRs were seen as early as 1 week after eculizumab therapy initiation and continued to occur over 26 weeks of therapy. Although transplantation historically has been contraindicated in patients with aHUS, no patient who entered the study with a kidney transplant lost the transplant after 26 weeks. Together, these findings confirm the disease-modifying effects of eculizumab, including maintenance or improvement of existing kidney function and protection of kidney transplants.

In the current trial, eculizumab treatment was initiated approximately 1 month after diagnosis, a substantially shorter duration than in the 2 pivotal trials (which had median intervals prior to treatment of 9.7 months in patients with aHUS with progressing TMA and 48.3 months in those with long disease duration and CKD). Evidence from these pivotal trials and case studies of patients with aHUS demonstrate that earlier initiation of eculizumab therapy is associated with significantly greater improvements in kidney disease outcomes. A larger proportion (54%) of patients in the current study met criteria for improvement in eGFR by ≥15 mL/min/1.73 m² compared to the pivotal trial of patients with long disease duration and CKD (5%). The proportion of patients having this eGFR improvement and overall change from baseline in eGFR were similar in the

![Figure 5. Mean change from baseline in patient EQ-5D United States time trade-off score over 26 weeks of eculizumab treatment.Bars represent standard error. A change from baseline of 0.06 in EQ-5D score is considered clinically meaningful.\(^*\) \(P \leq 0.05; \) \(P \leq 0.01\). Only n > 5 are shown.](image)
current study and the pivotal study of patients with progressing TMA.\textsuperscript{14} Thus, data from the current study provide further evidence for the recommendation to diagnose aHUS accurately and quickly and initiate early treatment with eculizumab in order to prevent rapid progression and potentially life-threatening consequences of TMA.\textsuperscript{6}

In the current study, benefits of eculizumab were demonstrated in an adult patient population including 34% with normal platelet counts and 20% with only moderately reduced kidney function (ie, eGFRs of 30-59 mL/min/1.73 m\textsuperscript{2}) at baseline. Diagnosis of aHUS can be particularly complex in adult patients.\textsuperscript{6} ADAMTS-13 (von Willebrand factor protease) activity can be evaluated to inform differential diagnosis with thrombotic thrombocytopenic purpura.\textsuperscript{21} It has been recommended\textsuperscript{9} that relatively higher serum creatinine levels (ie, $>3.2$ mg/dL) or platelet counts (ie, $>30 \times 10^3/\mu$L) at the time of TMA may be predictive of sufficient ADAMTS-13 levels and lower likelihood of thrombotic thrombocytopenic purpura diagnosis;\textsuperscript{22}; overall, the relative risk that patients presenting with TMA and values exceeding these thresholds do not have severely deficient ADAMTS-13 activity is 21.8 (P. Coppo, personal communication, May 2015). One should suspect aHUS in all patients with TMA,\textsuperscript{9,23} even without the most common presenting signs.

Overall, eculizumab was well tolerated in the study population and no unexpected safety signals or deaths were noted. The C5b-9 complex confers protection against encapsulated bacteria, particularly \textit{N meningitidis}, and its formation is blocked by eculizumab.\textsuperscript{1} Two cases of meningococcal infection were reported in the current trial; both patients recovered, and I remained on eculizumab therapy. In 1 case, the meningococcal serogroup was not identified and thus it is possible that the vaccine could not have protected the patient. A vaccine against serogroup B was recently approved for use in the European Union\textsuperscript{24} and may provide increased protection against meningococcal infection for patients with aHUS treated with eculizumab in the future. No reports of meningococcal disease have occurred in previous studies of eculizumab in aHUS, including in the 2-year follow-up of the pivotal trials\textsuperscript{12} and the concurrent pediatric trial.\textsuperscript{25} Based on an analysis of exposure to eculizumab in a real-world setting, meningococcal infection may be classified as an uncommon event (0.6 event/100 patient-years on eculizumab therapy in a 10-year study of patients with paroxysmal nocturnal hemoglobinuria\textsuperscript{26}). However, these cases highlight the necessity of vaccination against \textit{N meningitidis} before eculizumab therapy initiation and/or prophylactic antibiotic therapy and for continued vigilance for symptoms of meningococcal infection during therapy.

Elevated liver enzyme levels were noted in some patients prior to receiving the first dose of eculizumab and also in the postbaseline period in a smaller number of patients. Overall, there was a strong trend toward normalization of hepatic enzyme levels after initiation of eculizumab therapy. These findings suggest that the increases in alanine transaminase and aspartate aminotransferase levels that are present after eculizumab therapy initiation in some patients are most likely related to the pre-existing TMA. Importantly, these elevations were not associated with clinical AEs, and no patient discontinued eculizumab due to elevated liver enzyme levels or hepatic AEs.

The availability of eculizumab has profoundly changed the management of aHUS.\textsuperscript{27} This current study demonstrates that eculizumab effectively inhibits complement-mediated TMA, provides significant clinical benefits for adults with aHUS, and has a safety profile consistent with that reported from other clinical studies.\textsuperscript{14} Results from continued follow-up in this study and a separate long-term prospective trial are expected to provide further insights regarding eculizumab for the treatment of aHUS.

ACKNOWLEDGEMENTS

These data have been presented in part at Kidney Week, November 5-10, 2013, Atlanta, GA, and the 55th American Society of Hematology Annual Meeting and Exposition, December 7-10, 2013, New Orleans, LA.

We thank the following investigators: Columbia University Medical Center, New York, NY: David Cohen; Lahey Clinic, Burlington, MA: Mary Ann Simpson, Monica Grafals; Hackensack University Medical Center, Hackensack, NJ; Kenneth Lieberman; Hospital Bretonneau-Service Néphrologie, Tours, France; Yvon LeBranchu; Pôle Urologie-Néphrologie Hôpital Pasteur, Nice, France: Elisabeth Cassuto-Viguier; CHRU de Caen–Hôpital Clémenceau, Caen, France: Hurault De Ligny; Universitätsklinikum Essen, Essen, Germany: Oliver Witzke, Thorsten Feldkamp; Careggi University Hospital, Firenze, Italy; Elisabetta Berton; Royal Devon and Exeter National Health Service Foundation Trust, Exeter, United Kingdom: Coralie Bingham; Freeman Hospital, Newcastle, United Kingdom: Neil Sheerin.

Support: This study was sponsored by Alexion Pharmaceuticals Inc, the manufacturer of eculizumab. The authors acknowledge Kenyon Ogburn, PhD, Erin Harvey, MS, and John F. Kincaid, MD, of Alexion Pharmaceuticals Inc and Kristen W. Quinn, PhD, of Peloton Advantage, LLC who provided medical writing/editorial support with funding from Alexion Pharmaceuticals Inc. The sponsor participated in study design, collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.

Financial Disclosure: Dr Fakhouri has received a travel grant and consultancy fees from Alexion Pharmaceuticals Inc. Dr Campistol has had consultancy agreements with, received research funding from, and has been a scientific advisor or board member for Alexion Pharmaceuticals Inc; has had consultancy agreements with Pfizer, Wyeth, Novartis Pharmaceuticals, and Roche; has received research funding from Pfizer and Novartis Pharmaceuticals; and has been a scientific advisor or board member for Novartis Pharmaceuticals and Pfizer. Dr Cataland has received research funding from Alexion Pharmaceuticals Inc. Dr Espinosa.
Eculizumab in Adults With aHUS

has received consultancy fees from Alexion Pharmaceuticals Inc. Dr Gaber has received research funding from Alexion Pharmaceuticals Inc, Astellas Pharma US Inc, Novartis Pharmaceuticals, LifeCycle Pharma Inc, Quark Pharmaceuticals, Genzyme, Roche, Pfizer, Isoteknika Pharma Inc, Angion Biomedica Corp, Grifols, and BioPorto Diagnostics. Dr Menne has received travel grants and consultancy fees from Alexion Pharmaceuticals Inc, Berlin-Chemie, Daiichi-Sankyo, and Novartis Pharmaceuticals. Dr Minetti has received research support/travel grants from Sanofi, Bristol-Myers Squibb, Novartis Pharmaceuticals, and Astellas Pharma US Inc. Dr Rondeau has received travel grants and consultancy fees from Alexion Pharmaceuticals Inc. Drs Ogawa and Bedrosian are employees and stock shareholders of Alexion Pharmaceuticals Inc. Dr Weekers has received grant/research support from Roche, Novartis Pharmaceuticals, and Astellas Pharma US Inc. Dr Legendre has received travel grants and lecture fees from Alexion Pharmaceuticals Inc, travel grants from CSL Behring and Novartis Pharmaceuticals, and lecture fees from Astellas Pharma US Inc, CSL Behring, and Novartis Pharmaceuticals. Drs Hourmant, Provôt, and Ruggenenti declare that they have no other relevant financial interests.

Contributions: Research idea and study design: MO, CLB; data acquisition: MO, CLB; data analysis/interpretation: all authors; statistical analysis: MO, CLB; supervision or mentorship: all authors. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. FF takes responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.

Peer Review: Evaluated by 2 external peer reviewers, a Statistical Editor, a Co-Editor, and the Editor-in-Chief.

SUPPLEMENTARY MATERIAL

Table S1: Ethics committee approvals at centers enrolling patients.
Table S2: Treatment-emergent AEs occurring in ≥15% of patients.
Table S3: Serious treatment-emergent AEs.
Table S4: Patients with meningococcal infections.
Item S1: Health-related quality-of-life measures.
Item S2: Pharmacokinetics and pharmacodynamics.

Note: The supplementary material accompanying this article (http://dx.doi.org/10.1053/j.ajkd.2015.12.034) is available at www.ajkd.org

REFERENCES